Hansa Biopharma AB (publ) (STO:HNSA)
Sweden · Delayed Price · Currency is SEK 31.48
-0.68 (-2.11%)
Jan 21, 2026, 12:43 PM CET
Hansa Biopharma AB Revenue
Hansa Biopharma AB had revenue of 30.80M SEK in the quarter ending September 30, 2025, a decrease of -36.70%. This brings the company's revenue in the last twelve months to 178.61M, down -5.69% year-over-year. In the year 2024, Hansa Biopharma AB had annual revenue of 171.32M with 27.76% growth.
Revenue (ttm)
178.61M
Revenue Growth
-5.69%
P/S Ratio
18.32
Revenue / Employee
1.34M
Employees
135
Market Cap
3.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 171.32M | 37.22M | 27.76% |
| Dec 31, 2023 | 134.09M | -20.43M | -13.22% |
| Dec 31, 2022 | 154.53M | 120.65M | 356.12% |
| Dec 31, 2021 | 33.88M | 27.78M | 455.56% |
| Dec 31, 2020 | 6.10M | 2.73M | 81.27% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Saniona AB | 743.21M |
| BioInvent International AB | 244.85M |
| Genovis AB (publ.) | 117.66M |
| Oncopeptides AB | 62.47M |
| Egetis Therapeutics AB | 55.40M |
| Vicore Pharma Holding AB | 8.50M |
| Xspray Pharma AB | 3.81M |
| Flerie AB | 2.50M |
Hansa Biopharma AB News
- 6 days ago - Hansa Biopharma AB at JPMorgan Healthcare Conference Transcript - GuruFocus
- 6 days ago - Hansa Biopharma AB (publ) (HNSBF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation - PRNewsWire
- 2 months ago - Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases Transcript - Seeking Alpha
- 2 months ago - Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases - Slideshow - Seeking Alpha
- 2 months ago - Hansa Biopharma AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 2 months ago - Hansa Biopharma AB (publ) (HNSBF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Hansa Biopharma AB (HNSBF) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst Revenue ... - GuruFocus